Overview
Founded in 1949, Medtronic has grown to become the world's largest independent medical technology company. At the core of all we do is our Mission: to alleviate pain, restore health and extend life. It provides a clear path for all employees as we work together to take Medtronic to the next level.
Medtronic was first incorporated April 23, 1957 and became a public company as the result of a convertible debenture offering. The first shares were issued under these debentures on December 17, 1959 to our company founders, Earl Bakken and Palmer Hermundslie. Medtronic shares were traded Over-the-Counter (OTC) until we were listed on the NASDAQ in 1964. Medtronic began trading on the New York Stock Exchange on November 21, 1977 and continues to be traded on the NYSE today under the ticker symbol MDT.
| Date | Title | | 01/27/12 | Medtronic Launches New Minimally Invasive Cardiac Surgery Products Through Exclusive Distribution Agreement with Miami Instruments| MINNEAPOLIS--(BUSINESS WIRE)--Jan. 27, 2012--
Medtronic, Inc. (NYSE: MDT) today announced that it has entered into an
exclusive distribution agreement with Miami Instruments, LLC – a company
focused on the design of innovative surgical instruments for minimally
invasive cardiac surgery (MICS) procedures – and has introduced the
company’s first two products in the U.S.
The first products launched are the Joseph Lamelas Knot Pusher™, which
... |
| | 01/24/12 | Medtronic Completes Enrollment of Extreme Risk Patient Group in
CoreValve(R) U.S. Pivotal Trial| CoreValve U.S. Trial to Continue Enrolling Patients in High Risk
Study, and Will Maintain Therapy Access to Extreme Risk Patients via
Continued Access Phase of Trial
MINNEAPOLIS, Jan 24, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it has completed patient
enrollment in the extreme risk study in its CoreValve U.S. Pivotal
Trial. The company also received approval from the U.S. Food and Drug
Administration (FDA) for an exten... |
| | 01/24/12 | Medtronic Completes Enrollment of Extreme Risk Patient Group in CoreValve® U.S. Pivotal Trial|
CoreValve U.S. Trial to Continue Enrolling Patients in High Risk
Study, and Will Maintain Therapy Access to Extreme Risk Patients via
Continued Access Phase of Trial
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012--
Medtronic, Inc. (NYSE: MDT) today announced it has completed patient
enrollment in the extreme risk study in its CoreValve U.S. Pivotal
Trial. The company also received approval from the U.S. Food and Drug
Administration (FDA) ... |
|
|
 |
| There are currently no events scheduled. |
